新型DHODH抑制剂作为强效广谱抗病毒药物的综合鉴定和机理评价

IF 4.8 3区 医学 Q2 CHEMISTRY, MEDICINAL
Pharmaceuticals Pub Date : 2025-09-20 DOI:10.3390/ph18091416
Chao Zhang, Shiyang Sun, Huiru Xie, Yongzhao Ding, Chun Hu, Jialin Guo, Junhai Xiao
{"title":"新型DHODH抑制剂作为强效广谱抗病毒药物的综合鉴定和机理评价","authors":"Chao Zhang, Shiyang Sun, Huiru Xie, Yongzhao Ding, Chun Hu, Jialin Guo, Junhai Xiao","doi":"10.3390/ph18091416","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives</b>: This study identifies novel dihydroorotate dehydrogenase (DHODH) inhibitors exhibiting potent broad-spectrum antiviral agents, particularly against influenza A virus (A/PR/8/34(H1N1)) and SARS-CoV-2. <b>Methods</b>: Structure-based virtual screening of 1.6 million compounds (ChemDiv and TargetMol databases) yielded 10 candidates, with compounds <b>6</b>, <b>9</b>, and <b>10</b> demonstrating significant anti-influenza activity (IC<sub>50</sub> = 4.85 ± 0.58, 7.35 ± 1.65, and 1.75 ± 0.28 μM, respectively). Building on these, molecular hybridization principles and scaffold hopping principles were applied to design and synthesize six novel compounds (<b>11</b>-<b>16</b>) through cyclization, coupling, and carboxylate deprotection. Prior to subsequent biological assays, the molecular structures of each compound were elucidated by NMR spectroscopy and MS. Their antiviral activities were subsequently assessed against both influenza virus and SARS-CoV-2. The compound <b>11</b>, demonstrating the most potent antiviral activity, was further subjected to surface plasmon resonance (SPR) analysis to assess its binding affinity for human DHODH. <b>Results</b>: Compound <b>11</b> emerged as the most potent DHODH inhibitor (<i>K</i><sub>D</sub> = 6.06 μM), exhibiting superior broad-spectrum antiviral activities (IC<sub>50</sub> = 0.85 ± 0.05 μM, A/PR/8/34(H1N1); IC<sub>50</sub> = 3.60 ± 0.67 μM, SARS-CoV-2) to the reported DHODH inhibitor (Teriflunomide<b>,</b> IC<sub>50</sub> = 35.02 ± 3.33 μM, A/PR/8/34(H1N1); IC<sub>50</sub> = 26.06 ± 4.32 μM, SARS-CoV-2). Mechanistic evaluations via 100 ns MD simulations and QM/MM calculations revealed stable binding interactions, particularly hydrogen bonds with GLN47 and ARG136, while alanine scanning mutagenesis confirmed these residues' critical roles in binding stability. <b>Conclusions</b>: This work identifies compound <b>11</b> as a potent broad-spectrum antiviral compound, offering a promising strategy for broad-spectrum antiviral therapy against RNA viruses by depleting pyrimidine pools essential for viral replication.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"18 9","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472551/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comprehensive Identification and Mechanistic Evaluation of Novel DHODH Inhibitors as Potent Broad-Spectrum Antiviral Agents.\",\"authors\":\"Chao Zhang, Shiyang Sun, Huiru Xie, Yongzhao Ding, Chun Hu, Jialin Guo, Junhai Xiao\",\"doi\":\"10.3390/ph18091416\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background/Objectives</b>: This study identifies novel dihydroorotate dehydrogenase (DHODH) inhibitors exhibiting potent broad-spectrum antiviral agents, particularly against influenza A virus (A/PR/8/34(H1N1)) and SARS-CoV-2. <b>Methods</b>: Structure-based virtual screening of 1.6 million compounds (ChemDiv and TargetMol databases) yielded 10 candidates, with compounds <b>6</b>, <b>9</b>, and <b>10</b> demonstrating significant anti-influenza activity (IC<sub>50</sub> = 4.85 ± 0.58, 7.35 ± 1.65, and 1.75 ± 0.28 μM, respectively). Building on these, molecular hybridization principles and scaffold hopping principles were applied to design and synthesize six novel compounds (<b>11</b>-<b>16</b>) through cyclization, coupling, and carboxylate deprotection. Prior to subsequent biological assays, the molecular structures of each compound were elucidated by NMR spectroscopy and MS. Their antiviral activities were subsequently assessed against both influenza virus and SARS-CoV-2. The compound <b>11</b>, demonstrating the most potent antiviral activity, was further subjected to surface plasmon resonance (SPR) analysis to assess its binding affinity for human DHODH. <b>Results</b>: Compound <b>11</b> emerged as the most potent DHODH inhibitor (<i>K</i><sub>D</sub> = 6.06 μM), exhibiting superior broad-spectrum antiviral activities (IC<sub>50</sub> = 0.85 ± 0.05 μM, A/PR/8/34(H1N1); IC<sub>50</sub> = 3.60 ± 0.67 μM, SARS-CoV-2) to the reported DHODH inhibitor (Teriflunomide<b>,</b> IC<sub>50</sub> = 35.02 ± 3.33 μM, A/PR/8/34(H1N1); IC<sub>50</sub> = 26.06 ± 4.32 μM, SARS-CoV-2). Mechanistic evaluations via 100 ns MD simulations and QM/MM calculations revealed stable binding interactions, particularly hydrogen bonds with GLN47 and ARG136, while alanine scanning mutagenesis confirmed these residues' critical roles in binding stability. <b>Conclusions</b>: This work identifies compound <b>11</b> as a potent broad-spectrum antiviral compound, offering a promising strategy for broad-spectrum antiviral therapy against RNA viruses by depleting pyrimidine pools essential for viral replication.</p>\",\"PeriodicalId\":20198,\"journal\":{\"name\":\"Pharmaceuticals\",\"volume\":\"18 9\",\"pages\":\"\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472551/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/ph18091416\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph18091416","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:本研究确定了新型二氢乙酸脱氢酶(DHODH)抑制剂,显示出有效的广谱抗病毒药物,特别是针对甲型流感病毒(A/PR/8/34(H1N1))和SARS-CoV-2。方法:通过ChemDiv和TargetMol数据库对160万个化合物进行结构虚拟筛选,筛选出10个候选化合物,其中化合物6、9和10具有显著的抗流感活性(IC50分别为4.85±0.58 μM、7.35±1.65 μM和1.75±0.28 μM)。在此基础上,应用分子杂交原理和支架跳变原理,通过环化、偶联和羧酸脱保护,设计合成了6个新化合物(11-16)。在随后的生物分析之前,每种化合物的分子结构都通过核磁共振波谱和质谱进行了阐明,随后评估了它们对流感病毒和SARS-CoV-2的抗病毒活性。化合物11显示出最有效的抗病毒活性,进一步进行表面等离子体共振(SPR)分析以评估其与人DHODH的结合亲和力。结果:化合物11是最有效的DHODH抑制剂(KD = 6.06 μM),具有较好的广谱抗病毒活性(IC50 = 0.85±0.05 μM, A/PR/8/34(H1N1);对报道的DHODH抑制剂(Teriflunomide, IC50 = 35.02±3.33 μM, A/PR/8/34(H1N1))的IC50 = 3.60±0.67 μM;IC50 = 26.06±4.32 μM, SARS-CoV-2)。通过100 ns MD模拟和QM/MM计算的机制评估显示了稳定的结合相互作用,特别是与GLN47和ARG136的氢键,而丙氨酸扫描诱变证实了这些残基在结合稳定性中的关键作用。结论:本研究确定化合物11是一种有效的广谱抗病毒化合物,通过耗尽病毒复制所必需的嘧啶库,为RNA病毒的广谱抗病毒治疗提供了一种有希望的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comprehensive Identification and Mechanistic Evaluation of Novel DHODH Inhibitors as Potent Broad-Spectrum Antiviral Agents.

Background/Objectives: This study identifies novel dihydroorotate dehydrogenase (DHODH) inhibitors exhibiting potent broad-spectrum antiviral agents, particularly against influenza A virus (A/PR/8/34(H1N1)) and SARS-CoV-2. Methods: Structure-based virtual screening of 1.6 million compounds (ChemDiv and TargetMol databases) yielded 10 candidates, with compounds 6, 9, and 10 demonstrating significant anti-influenza activity (IC50 = 4.85 ± 0.58, 7.35 ± 1.65, and 1.75 ± 0.28 μM, respectively). Building on these, molecular hybridization principles and scaffold hopping principles were applied to design and synthesize six novel compounds (11-16) through cyclization, coupling, and carboxylate deprotection. Prior to subsequent biological assays, the molecular structures of each compound were elucidated by NMR spectroscopy and MS. Their antiviral activities were subsequently assessed against both influenza virus and SARS-CoV-2. The compound 11, demonstrating the most potent antiviral activity, was further subjected to surface plasmon resonance (SPR) analysis to assess its binding affinity for human DHODH. Results: Compound 11 emerged as the most potent DHODH inhibitor (KD = 6.06 μM), exhibiting superior broad-spectrum antiviral activities (IC50 = 0.85 ± 0.05 μM, A/PR/8/34(H1N1); IC50 = 3.60 ± 0.67 μM, SARS-CoV-2) to the reported DHODH inhibitor (Teriflunomide, IC50 = 35.02 ± 3.33 μM, A/PR/8/34(H1N1); IC50 = 26.06 ± 4.32 μM, SARS-CoV-2). Mechanistic evaluations via 100 ns MD simulations and QM/MM calculations revealed stable binding interactions, particularly hydrogen bonds with GLN47 and ARG136, while alanine scanning mutagenesis confirmed these residues' critical roles in binding stability. Conclusions: This work identifies compound 11 as a potent broad-spectrum antiviral compound, offering a promising strategy for broad-spectrum antiviral therapy against RNA viruses by depleting pyrimidine pools essential for viral replication.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pharmaceuticals
Pharmaceuticals Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
6.10
自引率
4.30%
发文量
1332
审稿时长
6 weeks
期刊介绍: Pharmaceuticals (ISSN 1424-8247) is an international scientific journal of medicinal chemistry and related drug sciences.Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the maximum length of the papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信